ESR1 peptides vaccine study (Breast Cancer) - Clinical Trial

Email to Participate

What is the Purpose of this Study?

We are doing this study to find out if a new vaccine (ESR1 peptides) is safe and if they will help people with Estrogen receptor positive (ER+) breast cancer.

What is the Condition Being Studied?

Breast Cancer

Who Can Participate in the Study?

-Adults who:

--Are diagnosed with breast cancer

--Have completed chemotherapy or surgery.

Age Group

Adults

What is Involved?

If you choose to join this study you will:

-Get the study vaccine (ESR1 peptide)

-Return to the Duke Cancer Center for follow-up visits 6-8 times over 10 weeks.

-Be contacted by phone every 12 weeks to see how you are doing

-Have a skin biopsy (piece of skin will be taken) where the study vaccine was injected.

Study Details

Full Title

A Phase I Study of Cancer Peptides plus GM-CSF and Adjuvant Following Completion of Prescribed Systemic Therapy of Estrogen Receptor Positive Breast Cancer

Principal Investigator